Improving drug therapy for relapsed leukemia

A combination of two drugs showed promise in treating relapsed or refractory acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase 3 (FLT3) gene, according to a Northwestern Medicine study published ...


Update shows relatlimab + nivolumab slows advanced melanoma

For patients with previously untreated metastatic or unresectable melanoma, the combination of relatlimab + nivolumab continues to demonstrate a progression-free survival (PFS) benefit over nivolumab alone, according to updated ...

page 1 from 5